OLEMA PHARMACEUTICALS, INC. Cash and Restricted Cash
OLEMA PHARMACEUTICALS, INC. (OLMA) had Cash and Restricted Cash of $48.60 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.60M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $52.55M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.30M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35.26M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $48.60M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $52.55M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $48.30M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $35.26M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $52.47M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $50.64M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $139.48M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $35.89M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $16.89M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $33.72M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $68.54M 10-K · filed 2026-03-16 |
| 2023-09-30 | $117.41M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $34.96M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $40.92M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $23.70M 10-K · filed 2025-03-18 |
| 2022-09-30 | $26.80M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $24.53M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $21.51M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $13.81M 10-K · filed 2024-03-11 |
| 2021-09-30 | $25.60M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $50.42M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $47.88M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $338.55M 10-K · filed 2023-03-09 |
| 2020-09-30 | $127.82M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $50.48M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $27.91M 10-Q · filed 2021-05-11 |
| 2019-12-31 | $68.00K 10-K · filed 2022-02-28 |
| 2018-12-31 | $3.15M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |